Current Ocular Oncology and Pathology Trials


ARET0332, A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy

PI: G. Baker Hubbard MD
Status: Currently enrolling

Summary: This is a non-randomized study of patients with unilateral retinoblastoma treated with enucleation. The goals are to establish the prevalence of high risk histopathologic features and to demonstrate that patients without these features can be successfully treated with enucleation alone. In addition, the study aims to estimate the event free survival of patients with high risk features who are uniformly treated with adjuvant chemotherapy. Finally the study will estimate the incidence of toxicities associated with the proposed adjuvant chemotherapy.

Inclusion Criteria:
Patients between the ages of 0 and 6 with unilateral retinoblastoma treated with enucleation.

Exclusion Criteria:
Patients treated with any modality other than enucleation are not eligible.

Contact: Gigi Davis 404-785-2319 or Carla Shoffeitt 404-785-1150
Sponsor: Children's Oncology Group


Our Emory campus location:

Copyright © Emory Eye Center - All Rights Reserved | Emory Clinic Building B, 1365B Clifton Road, NE, Atlanta, Georgia 30322 USA